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Abstract Cancer chemoprevention is a new discipline whose foundation rests upon epidemiologic evidence
suggesting that dietary components such as beta-carotene, vitamin E, calcium and selenium may be inhibitors of
carcinogenesis. Over the last decade, as molecular and biochemical mechanisms of the carcinogenesis process have
been elucidated, the rationale of combining chemopreventive agents to target multiple pathways has strengthened. The
process of identifying potential synergistic combinations of chemoprevention agents should be based upon a systematic
process of preclinical development in vitro followed by testing in animal models of carcinogenesis. Surrogates of
anticarcinogenesis effects might include biochemical, molecular and pathologic assessment of tissue from animal
carcinogenesis models. If evidence of chemopreventive effect is found in animal models, systematic studies in humans
are indicated. These studies should include a careful Phase I trial to describe optimal chemoprevention doses for all
agents being tested in combination followed by Phase II trials to assess efficacy upon carcinogenesis biological and
pathological surrogates. J. Cell. Biochem. Suppl. 34:121–124, 2000. r 2000 Wiley-Liss, Inc.
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INTRODUCTION
Combinations of cytotoxic agents with non-
overlapping toxicity while enhancing therapeu-
tic effect has resulted in important treatment
advances for patients with lymphomas, child-
hood tumors, leukemias, and germinal cell neo-
plasms [DeVita, 1997]. Initial experimental data
in vitro and in vivo demonstrated enhanced
cytotoxic effects for combinations of cytotoxic
agents when compared to the same agents given
alone. Combinations of drugs selected had in
vitro evidence of additive or synergistic efficacy,
clinical evidence of single agent activity, and
toxicity profiles that differed sufficiently to al-
low for some, if not complete overlap [DeVita,
1997]. The concept of multiagent cytotoxic
therapeutics for cancer treatment became firmly
established in the 1960s with evidence of en-
hanced survival efficacy in childhood leukemias
and Hodgkins disease after combination cyto-
toxic chemotherapy when compared to single
agent chemotherapy [DeVita, 1997].
Can a similar rationale support the use of
combinations of chemopreventive agents to en-
hance anticarcinogenesis effect? If so, how might
the lessons learned from experience with combi-
nation cytotoxic agents be applied to drug or
micronutrient treatments aimed at preventing
cancer ? In the past, combinations of chemopre-
ventive agents have been based primarily upon
epidemiologic criteria. How should future che-
mopreventive agent combinations be devel-
oped? What existing mechanistic, preclinical
and clinical efficacy data are necessary prior to
initiation of clinical trials? How should efficacy
assessment of combinations of chemopreven-
tive agents proceed?
This short discussion addresses these issues
and suggests experimental paradigms that may
be preclinically and clinically tested.
CHEMOPREVENTIVE AGENT COMBINATIONS
USED IN LARGE RISK REDUCTION TRIALS
Cancer chemoprevention is a new discipline
whose foundation rests upon epidemiologic evi-
dence suggesting that dietary components in-
cluding vitamins and micronutrients such as
beta-carotene, vitamin E, calcium, and sele-
nium may be inhibitors of carcinogenesis. Re-
cently published risk reduction trials for chemo-
prevention of lung, esophageal, and gastric
cancers have employed combinations of chemo-
preventive agents [Blot et al., 1993; Heinonen
and Albanes, 1994; Omenn et al., 1996]. The
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micronutrient agents used in these large trials
were chosen primarily, but not solely, on the
basis of epidemiologic data. The CARET inves-
tigators carefully reviewed evidence of single
agent micronutrient efficacy in animal carcino-
genesis models [Peto et al., 1981]. They also
reviewed data in banked blood samples and
human epidemiologic data prior to initiation of
their trial of beta-carotene and retinol for lung
cancer risk reduction trial in smokers who had
stopped smoking. Despite this careful prelimi-
nary analysis, both this trial and a similar trial
in Finland [Heinonen and Albanes, 1994] failed
to demonstrate a reduction in lung cancer inci-
dence in the target population.
Blot et al. [1993] justified testing the chemo-
preventive activities of selenium, beta-caro-
tene, alpha-tocopherol, zinc, riboflavin and nia-
cin in Chinese subjects on the basis of
epidemiology, blood samples and experimental
animal dietary supplemental data. Specific nu-
tritional supplementation studies in combina-
tion of the proposed agents were not performed.
The multi-agent, factorial design made it diffi-
cult to discern the relative contributions of the
three chemopreventive agents administered to
the Chinese subjects.
In hind-sight, one is tempted to argue that
the failure of the two large prospective risk
reduction trials of beta-carotene in combination
with other micronutrients as a lung cancer
preventive may be due to the lack of prelimi-
nary mechanism-based data, of strong syner-
gism data in animal carcinogenesis models, and
of careful dose-response-toxicity data preclini-
cally and clinically. However, these large stud-
ies provide a wealth of exploitable insights into
the design, cost and execution of multi-agent
chemoprevention trials for the future.
MECHANISTIC RATIONALE FOR MULTIAGENT
CHEMOPREVENTION TRIALS
Although the precise biological mechanisms
of cellular carcinogenesis are incomplete, a num-
ber of specific mechanisms are well documented
to be procarcinogenic and may be explored in in
vitro and in vivo models. Table 1 lists potential
chemopreventive mechanisms. These mecha-
nisms have been categorized by the National
Cancer Institute into three broad categories: 1.
cancer blocking , 2. antioxidant, and 3. antipro-
liferation/antiprogression mechanisms. Enzy-
matic screening assays and in vitro methods
are used to assess agent-activity profiles in
each of these categories and contribute to an
overall assessment of the likelihood of anticar-
cinogenesis effect in humans [Steele et al., 1998].
The rapid pace of discovery of mechanisms of
cellular signal transduction, growth and apop-
tosis control will rapidly obsolesce this table.
Combinations of chemoprevention agents are
being designed to exploit multiple mechanisms
listed. For example, in animal models, all-trans-
N-(4-hydroxyphenyl)retinamide (antiprolifera-
tive and apoptosis induction) and tamoxifen
(modulation of growth factor and hormonal ac-
tivity—antiproliferation via different mecha-
nisms) appear to have synergistic chemopreven-
tive activity to prevent tumor recurrence in
N-methyl-N-nitrosourea treated rats [Ratko et
al., 1989]. The combination of DFMO (poly-
amine inhibition—antiproliferation) and piroxi-
cam (non-steroidal antiinflammatory inhibitor)
synergistically reduces the number, size, and
incidence of colon tumors in azoxymethane in-
duced colonic neoplasias [Rao et al., 1991]. Both
of these models are being clinically tested in
Phase I and II chemoprevention trials. Other
examples of proposed chemopreventive agent
combinations include N-acetyl-1-cysteine (anti-
oxidant) and oltipraz (antioxidant). The ratio-
TABLE I. Measurable and Targetable
Chemopreventive Mechanisms*
Cancer-Blocking Activities
Prevent carcinogen binding to DNA
Glutathione reduction













Modulation of growth factor and hormonal
activity
Angiogenesis inhibition
Arachidonic acid metabolism inhibition
Inhibition of basement membrane degradation
Prevention of oncogene activation
Stimulation of immune response
Promotion of intracellular communication
*Adapted from Steele et al. [1998] with permission.
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nale of combining two antioxidants rests in
dual mechanisms of enhancement of intracellu-
lar glutathione. Oltipraz enhances cellular syn-
thesis of glutathione while N-acetyl-l-cysteine
provides cysteine for glutathione synthesis.
Selective enzyme inhibitors should allow more
mechanism specific and targeting chemopreven-
tion combinations. For example, selective estro-
gen receptor inhibitors and nonsteroidal anti-
inflammatory agents have been approved for
non-cancer preventive indications. In a second-
ary endpoints analysis, raloxafene, a selective
estrogen-receptor inhibitor, reduces the risk of
breast cancer in women treated for control of
osteoporosis [Cummings et al., 1998]. Aspirin, a
known cardiovascular preventive reduces the
risk of colorectal cancer in large epidemiologic
cohorts.At least two more selective cyclooxygen-
ase-2 inhibitors are likely to enter the market
within the next year. Preliminary data in ani-
mal models supports the high potency of cy-
clooxygenase-2 inhibitors as colorectal cancer
chemopreventives [Kawamori et al., 1998]. With
specific protein kinase C inhibitors, antisense
oligonucleotides specific for signal transduction
genes under development, the likelihood for
pathway specific anticarcinogenesis therapeu-
tics is high. Combinations of pathway specific
agents will permit probing of cellular prolifera-
tive and apoptotic control pathways clinically.
Such a mechanistic approach to combined che-
mopreventive agent therapeutics is an attrac-
tive alternative to current methods of combina-
tion of chemopreventive agents.
PRELIMINARY DATA REQUIRED PRIOR TO
COMBINATION CHEMOPREVENTIVE
TRIALS IN HUMANS
Prior to human clinical trials of any new
drug, Food and Drug Administration standards
for each drug to be tested in combination for
safety should be met. This includes the determi-
nation of pharmacokinetic parameters in acute
and subchronic toxicity testing, reproductive
studies, and genotoxicity evaluation in animal
model systems. Proposed chemopreventive
agent combinations should also be evaluated in
at least one preclinical animal model system for
pharmacokinetic, toxicity, or enzyme interac-
tions [Steele et al., 1998]. Rao et al. [1991]
studied the chemopreventive action of 40% and
80% maximum tolerated doses levels of piroxi-
cam, difluoromethylornithine (DFMO), 16-a-
fluoro-5-androsten-17-one (DHEA analogue),
and ellagic acid in two and three drug combina-
tions. The two dose levels chosen were orally
administered to F344 rats given azoxymethane
as a colonic carcinogen. The DFMO-piroxicam
combination had enhanced anticarcinogenesis
effect over either alone. Although isobolic analy-
sis to define synergism was not possible in this
study design, this experiment provided impor-
tant data that support further clinical develop-
ment of the DFMO-piroxicam combination.
APPROACH TO HUMAN CLINICAL TRIALS
The dilemma of defining appropriate end-
points for early stage chemoprevention com-
pounds the problem of assessing multi-agent
chemopreventive combinations. To date, patho-
logic surrogate endpoints remain the preferred
approach to the preliminary assessment of che-
mopreventive efficacy. Surrogates such as co-
lonic polyps, actinic keratoses, cervical intraepi-
thelial neoplasia may be useful indicators of
interventional drug effect.
Phase I trials of chemopreventive agent com-
binations may consist of escalating doses of
each agent in groups of 3 to 6 subjects, treated
for a short period of time (14 to 28 days). In
addition to toxicity assessment, endpoints may
consist of drug effect endpoints in tissues such
as colonic mucosal prostaglandin content and
polyamine content for a DFMO-piroxicam Phase
I combination trial. As pathway-enzyme spe-
cific inhibitors become available, the target en-
zymes and products in morphologically normal
tissue and in pathologic surrogates may be as-
sayed for drug effect. A successful chemopreven-
tive agent combination combines evidence of
target-specific efficacy with acceptable clinical
toxicity. Maximum tolerable doses need not be
defined. Rather, optimal doses that can repro-
ducibly alter a known biochemical target in a
large proportion of healthy human subjects
(.67%) are defined in the Phase I trial. Al-
though time consuming, these Phase I trials
have great importance in defining the best suit-
able dose and schedule for a given combination.
Since the goal of chemopreventive interven-
tions is to protect cells from carcinogenic stress
or slow or stem the carcinogenesis process, defi-
nition of maximum tolerable doses is not essen-
tial. Rather, Phase I trials of chemopreventive
agent combinations should identify safe and
effective doses the alter a carcinogenesis end-
point for each agent in the combination.
Multiagent Chemoprevention 123
Once Phase I trials identify effective combina-
tion doses, Phase IIa and IIb clinical trials to
assess chemopreventive effect upon surrogate
endpoints may proceed. Phase II trials provide
sufficient data to determine whether the anti-
carcinogenesis effect of a combination of chemo-
prevention agents is sufficient to warrant a
large risk reduction trial. Phase IIa trials may
complete or refine combination dose and sched-
ule by an open label, randomized design with a
tissue surrogate or biological surrogate end-
point. Phase IIb trials are randomized, blinded
trials of intermediate treatment lengths (6
months to a year) with tissue surrogate end-
points, biological surrogate endpoints or both.
The design of these trials provide sufficient
data and statistical power to define a combina-
tion’s potential as cancer risk reduction treat-
ment and whether a risk reduction trial should
be undertaken.
SUMMARY AND CONCLUSIONS
Given the current state of the art in chemopre-
ventive agent development, combining agents
to obtaining sufficient preliminary data in hu-
mans to justify testing in large, risk reduction
trials is a challenging, high risk but high gain
endeavor. Prior experience in large cohort,
multinutrient risk reduction chemoprevention
trials suggests that more careful preliminary
efforts in smaller cohorts using biological surro-
gates of cellular transformation or carcinogen-
esis are indicated. Preliminary data in animal
models of chemical or transgenic carcinogen-
esis provides necessary information regarding
dose, frequency, and synergism that may be
used to justify clinical development of combina-
tion agents. Human Phase I trials to define
optimal anticarcinogenesis combination chemo-
preventive doses upon a surrogate endpoint are
necessary prior to efficacy assessments in Phase
II or III. Exploiting anticarcinogenic targeting
agents in a sequence aimed at reducing cellular
proliferative signals while enhancing apoptotic
function may be an optimal future approach to
the design and testing of chemopreventive agent
combinations.
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